|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 90 No. 5 (September 1), 1997:
pp. 1768-1776
RAPID COMMUNICATION
STAT5A-Deficient Mice Demonstrate a Defect in Granulocyte-Macrophage Colony-Stimulating Factor-Induced Proliferation and Gene Expression
By
Gerald M. Feldman,
Louis A. Rosenthal,
Xiuwen Liu,
Mark P. Hayes,
Anthony Wynshaw-Boris,
Warren J. Leonard,
Lothar Hennighausen, and
David S. Finbloom
From the Division of Cytokine Biology, Center for Biologics Evaluation and Research, Food and Drug Administration; the Laboratory of Biochemistry and Metabolism, National Institute of Diabetes and Digestive and Kidney Diseases, NIH; the Laboratory of Genetic Disease Research, National Human Genome Research Institute, NIH; and the Laboratory of Molecular Immunology, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD.
 |
ABSTRACT |
Responses of cells to cytokines typically involve the activation of a family of latent DNA binding proteins, referred to as signal transducers and activators of transcription (STAT) proteins, which are critical for the expression of early response genes. Of the seven known STAT proteins, STAT5 (originally called mammary gland factor) has been shown to be activated by several cytokines, such as granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), and IL-5, which are known to play important roles in growth and differentiation of hematopoietic precursors. In this report we have used mice that are deficient in STAT5A (one of two homologues of STAT5) to study the role of STAT5A in GM-CSF stimulation of cells. When bone marrow-derived macrophages were generated by differentiation with macrophage-CSF (M-CSF), exposure of cells from wild-type mice to GM-CSF resulted in a typical pattern of assembly of DNA binding proteins specific for the gamma activation sequence (GAS) element within the  -casein promoter. However, in cells from the STAT5A null mouse one of the shifted bands was absent. Immunoblotting analysis in the null mice showed that lack of STAT5A protein resulted in no alteration in activation of STAT5B by tyrosine phosphorylation. Proliferation experiments revealed that, when exposed to increasing concentrations of GM-CSF, cells derived from the null mice grew considerably more slowly than cells derived from the wild-type mice. Moreover, expression of GM-CSF-dependent genes, CIS and A1, was markedly inhibited in cells derived from null mice as compared with those of wild-type mice. The decreased expression observed with A1, a bcl-2 like gene, may account in part for the suppression of growth in cells from the null mice. These data suggest that the presence of STAT5A during the GM-CSF-induced assembly of STAT5 dimers is critical for the formation of competent transcription factors that are required for both gene expression and cell proliferation.
| |
INTRODUCTION |
CYTOKINES, such as interferons (IFNs), regulate the growth, differentiation, and functional status of cells within the immune system by activation of a family of transcription factors known as signal transducers and activators of transcription (STATs), which bind to specific enhancers and induce expression of early response genes that are thought to be critical for these events.1 These proteins are latent transcription factors that are activated by tyrosine phosphorylation following binding of specific ligands to cognate receptors, leading to the dimerization and subsequent translocation of the STAT proteins to the nucleus.2 Although initially thought to be a unique characteristic of IFN-mediated signaling, most cytokines have been shown to activate STATs, which in most cases play important roles in mediating the specific actions of these cytokines.3 We previously have defined a STAT-like protein, unrelated to those STAT proteins activated by IFNs, that was activated by granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), and IL-5, all of which bind to receptors that share a common chain (c ).4 This protein, initially characterized by others as a growth factor for mammary tissue (termed mammary gland factor),5 has subsequently been renamed STAT5 and demonstrated to be activated by several groups of cytokines.6-8
Once it became apparent that activation of STAT5 occurred in response to these cytokines, the role of STAT5 in cell proliferation and differentiation was assessed by transfecting dominant negative constructs of STAT5 into cell lines and evaluating their effects on proliferation and differentiation. In one study,9 a dominant negative STAT5 suppressed IL-3-induced growth. However, in another study10 there was no effect on the rate at which cells lost viability after removal of IL-3 from the cultures. Other studies have commented on the ability of either IL-3 or GM-CSF to induce c-fos and the role of AP-1 on downstream proliferative effects. Other cytokines that activate STAT5 have also been evaluated with respect to the effects of STAT5 activation on proliferation, yielding disparate results.11
During studies of STAT5 activation, it became evident that there were two separate STAT5 molecules, referred to as STAT5A and STAT5B.12-14 STAT5A and STAT5B have molecular weights of about 94 and 92 kD, respectively, varying primarily by 12 amino acids at the carboxyl terminal end. These proteins are encoded by separate but closely linked genes. Moreover, these proteins can also be expressed as lower molecular weight forms of about 80 kD.8,13 Indeed, it was this 80-kD form that was isolated by our laboratory initially as a STAT-like protein activated by GM-CSF.4 Subsequently, we have shown that both the full-length proteins and the 80-kD protein can be isolated from human monocytes, and that in these cells the 80-kD protein was entirely STAT5A derived.8 Interestingly, no 80-kD STAT5A proteins were observed in human T cells. In murine cells, both STAT5A and STAT5B have been shown to have an 80-kD form, which was presumed to be a carboxyl terminal truncation that may function as a dominant negative transcription factor.9,10,15
The role of STAT5 in the cytokine-mediated control of cell growth and differentiation remains clouded by conflicting data; inhibition of STAT5 activation suppressed proliferative responses in some systems but not in others. Clearly, the use of mice deficient in one or both STAT5 homologues would allow for a better determination of the effects of STAT5 on gene expression and cell proliferation. STAT5A-deficient mice have now been generated using gene targeting.16 These mice have been shown to have marked defects in mammary gland development and lactogenesis. We have used these mice to study the effects of the lack of STAT5A on the activation of myeloid cells by GM-CSF.
| |
MATERIALS AND METHODS |
Mice.
The generation of STAT5A-deficient mice by targeted disruption of the STAT5A gene has been previously described.16 Heterozygous mice were intercrossed to generate wild-type, heterozygous, and STAT5A null mice. In some experiments, STAT5A null mice with a 129SvEv inbred background were used instead of the original null mice, which had been established in a NIH Black Swiss/129SvEv hybrid background.
Bone marrow (BM) culture-derived macrophages.
Femurs and tibias were aseptically removed, and the marrow was washed out by syringe using a 25-gauge needle and Dulbecco's modified Eagle medium (DMEM). After drawing the cells through the syringe several times to break up the clumps, the cells were cultured in 100-mm Petri dishes (Falcon; 1029; Becton Dickinson Labware, Lincoln Park, NJ) in DMEM containing 10% fetal bovine serum (FBS), 50 µg/mL gentamycin, and 100 ng/mL recombinant human macrophage colony-stimulating factor (M-CSF) (Chiron, Emeryville, CA). Spent culture fluid was exchanged with fresh medium every 3 to 4 days. Under these conditions, confluent monolayers of macrophages were obtained within 7 to 10 days.17 BM-derived macrophages were obtained by gently scraping with a plastic policeman after incubating the monolayers with phosphate-buffered saline (PBS) containing 5 mmol/L EDTA for 5 to 10 minutes. Cells were washed free of M-CSF and cultured in DMEM containing FBS for 24 hours before use. Cell viability was determined by trypan blue exclusion and verified to be greater than 90% before performing an experiment. Cells were treated with various concentrations of recombinant murine GM-CSF (Pharmingen, San Diego, CA) for various times.
Electrophoretic mobility shift assays (EMSA).
Cells were washed with cold PBS and scraped into an ice-cold whole cell extraction buffer containing 0.1% Triton X-100 (Pierce, Rockford, IL), 10 mmol/L HEPES (pH 7.3), 400 mmol/L KCl, l mmol/L dithiothreitol, 2 mmol/L EDTA, 1 mmol/L EGTA, 1 mmol/L sodium orthovanadate, 10% glycerol, 1 mmol/L phenylmethylsulfonyl fluoride (PMSF), and 5 µg/mL each of aprotinin, leupeptin, and pepstatin. The extracts were vortexed for 10 seconds, incubated at 4°C for 10 minutes and centrifuged at 12,000g for 10 minutes to remove cell debris. Protein concentrations for each extract were determined, and equal amounts of protein were assayed for DNA binding proteins by EMSA as previously described.18 Briefly, 32P-labeled double-stranded oligonucleotide probes, either the 21-bp GAS-like element from the promoter of the bovine -casein gene (5' AGATTTCTAGGAATTCAAATC 3')6 or the 39-bp IFN- response region (GRR) from the promoter of the human fcgrl gene (5' AGCATGTTTCAAGGATTTGAGATGTATTTCCCAGAAAAG 3')19 were incubated with the extracts (5 µg of protein) in binding buffer. The samples were then electrophoresed on a 6% nondissociating polyacrylamide gel to separate free probe from probe bound to protein. Supershift experiments were performed by incubating extracts with either normal rabbit serum or anti-STAT antibodies at a final concentration of 1:50 for 1 hour at 4°C before the addition of radiolabeled probe.
Immunoprecipitations and immunoblot analysis.
After treatment, cells (10 × 106/treatment group) were washed with cold PBS and solubilized in 1% Triton X-100 in a buffer consisting of 250 mmol/L NaCl, 50 mmol/L Tris-HCl, pH 7.4, 50 mmol/L NaF, 0.5 mmol/L Na pyrophosphate, 1 mmol/L sodium orthovanadate, 1 mmol/L PMSF, and 5 µg/mL each of aprotinin, leupeptin, and pepstatin. The postnuclear lysate was then precleared with a suspension of protein G agarose (Pharmacia, Piscataway, NJ) for 1 hour at 4°C. After separation of the protein G agarose from the lysate by centrifugation, the lysate was subdivided and incubated with either normal rabbit serum or rabbit anti-STAT5B14 for 2 to 18 hours at 4°C. Protein G agarose was then added for 1 hour at 4°C to isolate the immune complexes. The protein G conjugates were washed in lysis buffer and boiled in sodium dodecyl sulfate (SDS) sample buffer.
The samples were analyzed by 8% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) followed by electrophoretic transfer to polyvinylidene difluoride (PVDF) membranes (Immobilon-P; Millipore, Bedford, MA). The membranes were blocked using 1% ovalbumin (Sigma Chemical Co, St Louis, MO) in 150 mmol/L NaCl, 10 mmol/L Tris-HCI, pH 8.0 with 0.05% Tween 20 for 1 hour. Membranes were then incubated with the biotin-conjugated antiphosphotyrosine monoclonal antibodies (MoAbs) PY20 (Leinco, Ballwin, MO) and 4G10 (UBI, Lake Placid, NY) for at least 2 hours. After washing, the membranes were incubated with peroxidase-conjugated avidin (Southern Biotechnology, Birmingham, AL) and developed using enhanced chemiluminescence (Amersham, Arlington Heights, IL). The immunoblots were then reprobed with the immunoprecipitating anti-STAT5B antibody to show that equal amounts of protein were loaded onto each lane of the gel. These blots were developed using alkaline phosphatase-conjugated goat-antirabbit IgG (Southern Biotechnology) and nitroblue tetrazolium chemistry. In other experiments, whole cell extracts were analyzed by SDS-PAGE followed by immunblotting with anti-STAT5A, anti-STAT5B, or anti-STAT1. After washing, the membranes were probed with peroxidase-conjugated goat-antirabbit IgG and developed using enhanced chemiluminescence.20
Northern blot analysis.
Total cellular RNA isolated by the guanidine isothiocyanate procedure (Ambion, Inc, Austin, TX) was electrophoresed on 1% agarose gels containing 0.66% formaldehyde, transferred to nylon membranes (Duralon-UV; Stratagene, La Jolla, CA), and crosslinked to the membrane by ultraviolet light (UV Stratalinker; Stratagene). Membranes were prehybridized in a formamide-containing buffer (FastPair; Digene, Silver Spring, MD) at 42°C. The membrane-bound RNA was hybridized with radiolabeled probes under the same conditions. For probes, a 0.9-kb fragment of the cDNA for the  ytokine- nducible  H2-containing protein, CIS, was isolated by Sph I/Xho I digestion of the plasmid pME18S.21 The bcl-2 family member cDNA clone referred to as A1 was kindly provided by Drs Michael Prystowsky and Amos Orlofsky (Albert Einstein College of Medicine, Bronx, NY), and the 0.5-kb insert was isolated from the Bluescript SK(-) vector by digestion with Pst I/Xba I.22 The cDNA for glyceraldehyde-3-phosphate dehydrogenase (GAPDH), pRGAPD-13, has been previously described23; the insert was isolated by PstI digestion. The inserts were random primer labeled with 32P-dCTP to specific activities of 2 to 3 × 109 cpm/mg with the Klenow fragment of DNA polymerase I using random hexamers as primers.24 The membranes were washed twice in 2X saline-sodium citrate (SSC), 0.1% SDS at room temperature, and twice in 0.1X SSC, 0.1% SDS for 15 minutes each at 63°C and then exposed to Kodak XAR film (Eastman Kodak, Rochester, NY) at -70°C for different time intervals using intensifying screens. Filters were stripped by washing with boiling 0.05X SSC, 0.1% SDS. All signals were quantitated by phosphorimager analysis (Molecular Dynamics, Sunnyvale, CA) and normalized to GAPDH expression.
Cell proliferation analysis.
Cell proliferation was analyzed according to Mosmann.25 Briefly, confluent plates of BM-derived macrophages that had been starved of M-CSF for 24 hours were washed three times with PBS, and harvested in PBS containing 5 mmol/L EDTA by scraping. Optimal cell numbers and time in culture were determined before performing the proliferation analysis. Cells were plated in 96-well tissue culture dishes at 5 × 104 cells per well in 200 µL of DMEM containing 10% FBS and various concentrations of recombinant murine GM-CSF. After 5 days in culture, 25 µL of a 5 mg/mL solution of MTT (dimethyl thiazole diphenyl tetrazolium bromide; Sigma) in PBS was added to all wells and incubated for 2 hours at 37°C. After inversion of plates to remove liquid from the wells, 125 µL isopropanol/HCl (0.04 N HCl in 2-propanol) was added, and absorbance was read at 570 nm.
| |
RESULTS |
All mice appeared phenotypically normal at the time of birth and were raised in micro-isolator, filter-top cages without any apparent increase in the incidence of infectious diseases. The mice have been followed for up to 8 months without any apparent hematologic abnormalities. Total number of nucleated cells from the marrows of all three genotypes were indistinguishable. BM culture-derived macrophages were obtained from progenitor cells from the femurs and tibias of wild-type (WT, +/+), heterozygous (HZ, +/-), and STAT5A null mice (-/-). Extracts were obtained from these cells and assayed for the presence of STAT5A, STAT5B, and STAT1 by immunoblotting (Fig 1). There was a gene dosage effect in the cells from the three genotypes such that no STAT5A protein was present in the null mice, intermediate levels were observed in the HZ mouse, and normal levels were expressed in the WT mouse (Fig 1A). There was no difference in the level of expression of the STAT5B protein in the cells from the three groups (Fig 1B). Moreover, the expression of another STAT protein, STAT1, was unaffected by the absence of STAT5A (Fig 1C).
View larger version (12K):
[in this window]
[in a new window]
| Fig 1.
STAT5A protein expression in BM-derived macrophages from WT, HZ, and STAT5A null mice. Extracts (30 µg of protein per lane) of BM-derived macrophages from WT (+/+; lane 1), HZ (+/-; lane 2), and null (-/-; lane 3) mice were analyzed by SDS-PAGE followed by immunoblotting with (A) anti-STAT5A, (B) anti-STAT5B, or (C) anti-STAT1 as described in Materials and Methods. The membranes were developed by enhanced chemiluminescence.
|
|
We next investigated the ability of extracts from these cells to bind to the GAS element from the promoter of the -casein gene. Double-stranded, 32P-labeled -casein probe was incubated with extracts before separation of bound and free probe by nondissociating PAGE (Fig 2). In control, untreated cells there was no activation of complexes capable of binding to the -casein promoter (Fig 2, lanes 1 through 3). However, in cells treated with GM-CSF, there were three patterns of binding. Only a lowermost (c) and middle band (b) were observed in the null mouse (Fig 2, lane 4), whereas the lowermost (c), middle (b), and an uppermost band (a) were observed in the HZ mouse (Fig 2, lane 5). The WT mouse also showed bands (a) and (b), and, although in some experiments (Fig 2, lane 6) band (c) was difficult to observe, in other experiments (Fig 3) its presence was more evident. Furthermore, there was an increase in the intensity of band (a) in the WT compared with that observed in the HZ mouse (Fig 2, lane 6). Whether STAT5A or STAT5B were present in these shifted complexes was determined by "supershift" experiments. Extracts were incubated with anti-STAT antibody, and the loss of a band or a shift in the band was determined. Although incubation of extracts with normal rabbit serum (NRS) resulted in a minor nonspecific "supershift" band (Fig 3A-C, lane 3), there was essentially no loss of band intensity for any of the GM-CSF-induced shifted bands. For extracts from null mice, the predominant band (b) was only shifted by anti-STAT5B (Fig 3A, lane 5), and there was no shift with anti-STAT5A (Fig 3A, lane 4). For the WT mice, band (b) was partially shifted by anti-STAT5A (Fig 3B, lane 4) or anti-STAT5B (Fig 3B, lane 5) and totally shifted by addition of both antibodies (Fig 3B, lane 6). The content of the STATs in band (a) was difficult to assess because the lower bands were displaced into this band upon supershifts with antibodies such as the anti-STAT5B (Fig 3A, lane 5). The pattern of displacement of shifted bands in the HZ mice was similar to that of the WT mice (Fig 3C). For extracts derived from null, HZ, and WT mice, the addition of an anti-STAT1 antibody totally eliminated band (c) (Fig 3A-C, lane 7). Because responses to GM-CSF were observed in all three genotypes, changes in receptor structure seems to be an unlikely cause for these observations. EMSA and supershift experiments using the GRR probe yielded similar results (data not shown).
View larger version (42K):
[in this window]
[in a new window]
| Fig 2.
GM-CSF induction of GAS-binding complexes in BM-derived macrophages from STAT5A null, HZ, and WT mice. BM-derived macrophages from null (-/-; lanes 1 and 4), HZ (+/-; lanes 2 and 5), and WT (+/+; lanes 3 and 6) mice were incubated with either medium (lanes 1-3) or 10 ng/mL of GM-CSF (lanes 4-6) for 15 minutes at 37°C, and whole cell extracts (5 µg of protein per lane) were analyzed by EMSA using the 32P-labeled -casein probe as described in Materials and Methods. Arrows labeled a, b, and c indicate the uppermost, middle, and lowermost bands containing GAS-binding complexes, respectively.
|
|
View larger version (63K):
[in this window]
[in a new window]
View larger version (71K):
[in this window]
[in a new window]
| Fig 3.
Characterization of the GAS-binding STAT protein complexes in GM-CSF-stimulated BM-derived macrophages from STAT5A null, WT, and HZ mice. BM-derived macrophages from null (A), WT (B), and HZ (C) mice were incubated with either medium (lane 1) or 10 ng/mL of GM-CSF (lanes 2-7) for 15 minutes at 37°C, and whole-cell extracts (5 µg of protein per sample) were analyzed by EMSA using the 32P-labeled -casein probe as described in Materials and Methods. Extracts were preincubated with NRS (which resulted in a nonspecifically displaced band near the top of the gel) or the indicated anti-STAT antibodies before the addition of the probe. Arrows labeled a, b, and c indicate the uppermost, middle, and lowermost bands containing GAS-binding complexes, respectively.  5A, anti-STAT5A; 5B, anti-STAT5B; p91, anti-STAT1.
|
|
The role of STAT5A in the control of activation of STAT5B in hematopoietic cells is unexplored. Exposure of mammary tissue to prolactin during pregnancy results in the activation of both STAT5A and STAT5B equally well as determined by tyrosine phosphorylation.26 However, in STAT5A null mice there was noted to be a marked decrease in the ability of STAT5B to be tyrosine phosphorylated during pregnancy.16 To explore whether there was a similar requirement of STAT5A for GM-CSF-induced tyrosine phosphorylation of STAT5B, we exposed BM-derived macrophages to GM-CSF and measured tyrosine phosphorylation of STAT5B by immunoblotting with anti-phosphotyrosine antibodies. Equal numbers of cells were either left untreated or treated with GM-CSF for 15 minutes and then solubilized before immunoprecipitation with anti-STAT5B. Immunoblotting showed that GM-CSF could still induce the tyrosine phosphorylation of STAT5B in cells from null mice (Fig 4A, lanes 1-6). Reprobing of the immunoblot revealed that equal quantities of protein were loaded within each lane (Fig 4B, lanes 1-6).
View larger version (25K):
[in this window]
[in a new window]
| Fig 4.
GM-CSF-induced tyrosine phosphorylation of STAT5B in BM-derived macrophages from WT, HZ, and STAT5A null mice. (A) BM-derived macrophages from WT (lanes 1 and 2), HZ (lanes 3 and 4), and null (lanes 5 and 6) mice were incubated with either medium (lanes 1, 3, and 5) or 10 ng/mL of GM-CSF (lanes 2, 4, and 6) for 15 minutes at 37°C and then solubilized in a buffer containing 1% Triton X-100. STAT5B was immunoprecipitated from the lysates with anti-STAT5B, and the immunoprecipitates were analyzed by SDS-PAGE followed by immunoblotting as described in Materials and Methods. The membrane was probed with the antiphosphotyrosine MoAbs PY20 and 4G10, and developed by enhanced chemiluminescence. STAT5BP denotes tyrosine phosphorylated STAT5B. (B) The amount of protein loaded within each lane of the gel was determined by reprobing the immunoblot with the immunoprecipitating anti-STAT5B antibody and developing the blot with nitroblue tetrazolium chemistry.
|
|
To assess whether the absence of STAT5A would affect expression of GM-CSF-induced genes including one (A1) which may influence proliferation, we measured steady-state levels of two genes known to be activated by GM-CSF: the CIS and A1 genes. Although both are known to be induced as early response genes following treatment with GM-CSF, only the CIS gene has been shown to have STAT5 binding elements within the promoter region. Cells were removed from M-CSF for 24 hours before stimulation with GM-CSF for various times. Total cellular RNA was isolated, and Northern analysis was performed. For the CIS gene, there was a gene dosage-dependent decrease in the ability of GM-CSF to induce CIS expression, with cells from WT, HZ, and null mice having the highest, intermediate, and lowest levels of expression, respectively (Fig 5A and B). Results for the GM-CSF-dependent gene, A1, were not dissimilar from that observed for the CIS gene (Fig 5A and C). Expression of A1 was also reduced (especially at the early time points) in the STAT5A null mice compared with that observed in cells from the WT and HZ mice.
View larger version (28K):
[in this window]
[in a new window]
| Fig 5.
Northern analysis of CIS and A1 mRNA induction in BM-derived macrophages. RNA was isolated from BM-derived macrophages from WT (+/+), HZ (+/-), and null (-/-) mice that had been treated for the indicated time periods with GM-CSF (10 ng/mL), and Northern analysis performed as described in Materials and Methods. The membrane was sequentially probed with CIS, A1, and GAPDH (GAP) probes (A). CIS (B) and A1 (C) mRNA levels normalized to levels of GAPDH (GAP) mRNA were plotted as a function of duration of GM-CSF exposure.
|
|
Although it has been reported that STAT5 is important for the growth of myeloid cells, the relative roles that the STAT5 isoforms play in controlling this growth have not been defined. To investigate this issue, we removed BM-derived macrophages from M-CSF for 24 hours before incubation with increasing concentrations of GM-CSF for 5 days, and the proliferative responses were measured by an MTT assay (Fig 6). At the lower doses of GM-CSF (<0.3 ng/mL) there was no differences in the proliferative responses between cells derived from WT and null mice. However, at higher doses of GM-CSF (>0.5 ng/mL) there were significant differences in the growth rate of the STAT5A null cells as compared with the WT cells (P < .05); at the highest dose studied there was a 33% inhibition of growth in the null cells, which was consistently observed in several experiments. At the concentrations of GM-CSF that resulted in logarithmic proliferation (between 0.5 and 5 ng/mL), cells from null mice required 5- to 10-fold more GM-CSF to obtain the same level of growth as that observed in the WT mice. Growth curves for the HZ mice were intermediate between the null and WT mice (data not shown).
View larger version (15K):
[in this window]
[in a new window]
| Fig 6.
Proliferative response of BM-derived macrophages to GM-CSF. BM-derived macrophages pooled from multiple inbred WT(+/+) and null (-/-) mice (5 × 104/well) were incubated with the indicated concentrations of GM-CSF for 5 days, and the proliferative response was assayed by the MTT assay as described in Materials and Methods. Results are presented as the mean ± the standard deviation of triplicate determinations. This experiment is representative of five independent experiments. Asterisks denote a significant difference (P < .05) in proliferation between cells from WT and null mice at that dose (Student's t-test).
|
|
| |
DISCUSSION |
Induction of early response genes and subsequent phenotypic changes within cells after exposure to cytokines are frequently the result of activation of latent transcription factors referred to as STATs. For members of the family of cytokines that activate cells through receptors that share a subunit (IL-3, IL-5, and GM-CSF), the STAT protein that is most frequently activated is STAT5.27 STAT5 is both tyrosine and serine phosphorylated, translocates to the nucleus very rapidly, and is required for expression of several genes known to have STAT5 binding elements within their promoter.28 It has recently been appreciated that STAT5 consists of two homologues: STAT5A and STAT5B.12,14,26 Both proteins are usually present in cells, and both are activated by cytokines to form homodimers and heterodimers. The presence of a mouse model with the STAT5A gene disrupted by gene targeting allowed us to determine the role of STAT5A in the activation of cells by GM-CSF. We show that the absence of STAT5A results in clear differences in the ability of cells to assemble DNA-protein complexes in response to GM-CSF. This defect apparently results in diminished proliferation in response to GM-CSF and decreased expression of GM-CSF-dependent genes.
The GAS element in the promoter of the -casein gene binds GM-CSF-activated STATs such that three distinct bands become shifted during an EMSA (see Fig 2). Although we did not observe the activation of STAT1 by GM-CSF in human peripheral blood monocytes,4 band (c) derived from the GM-CSF-stimulated BM-derived macrophages is clearly supershifted by an antibody specific for STAT1. Therefore, it appears that these cells can activate STAT1 in response to GM-CSF. Moreover, for reasons that are unclear, it appears that more STAT1 is activated in cells from the HZ mice than from null or WT mice. The most obvious difference between the null mice and the other two genotypes is the lack of band (a) (Fig 2, lane 4). Therefore, this band must represent either STAT5A homodimers or STAT5A-STAT5B heterodimers. It is also apparent that homodimers of STAT5B can migrate within band (b). This band could also be composed of STAT5A and STAT5B homodimers. The lack of STAT5A in band (a), which is also presumably the greatest in molecular weight, may imply that this band represents dimer-dimer formations between STAT5A and STAT5B. It has recently been shown for STAT1 and STAT4 that the ability to form tetramers consisting of two dimers on adjacent elements in the promoters of responsive genes may be critical for initiating cytokine-mediated gene induction.29,30 Indeed, it is clear (see Fig 2) that the amount of band (a) increases from nothing in the null mice, to intermediate levels in the HZ mice, and then to maximal levels in the WT mice. Such slower migrating bands on EMSA have been previously reported to be associated with STAT tetramer formation.30
Studies on a transgenic mouse strain with impaired mammary gland development have suggested that in mammary tissues the inability to express the whey acidic milk protein correlates with the lack of assembly of STAT5A/STAT5B heterodimers.26 This has been confirmed in the STAT5A-deficient mouse in that females, who do not lactate, cannot form STAT5A/STAT5B heterodimers and do not express the WAP milk protein.16 These results are highly suggestive of the possibility that the formation of STAT5A/STAT5B heterodimers may be critical for the induced expression of GM-CSF-dependent genes. This was also alluded to through the use of a STAT5A mutant construct that reduced the expression of STAT5-dependent genes such as CIS but not genes such as c-fos and myc.10 We have similarly shown that cells from STAT5A-deficient mice show a dramatically reduced ability to express a gene that is clearly dependent on STAT5, namely the CIS gene. Moreover, we were able to show that this inhibition occurs in a gene dosage-dependent manner. Although not as marked as the results with the CIS gene, the reduction in expression of the A1 gene is clearly evident in the null mice. Whether the differences in the results for CIS and A1 expression are due to differences in STAT5 binding sites within the promoters will require further study because the A1 promoter has only been partially sequenced.31 The ability of WT and HZ cells to respond to GM-CSF with enhanced A1 expression may, in part, explain their ability to demonstrate greater proliferation. If A1 functions as a bcl-2-like gene,22 enhanced expression should protect these cells from apoptosis.
BM-derived macrophages are sensitive to both M-CSF and GM-CSF with respect to the ability of these cytokines to induce proliferation and promote survival. BM precursor cells were expanded originally in M-CSF because this cytokine activates essentially no STAT5 in our system. Once starved of M-CSF for 24 hours, cells were incubated with increasing concentrations of GM-CSF and the proliferative response was measured. The curves generated from the WT mice start to separate from those of the null mice at a concentration of about 0.3 to 0.8 ng/mL in most of the experiments performed. At this dose of GM-CSF only a portion of the receptors (about 20% to 60%; D.S.F., unpublished observations) are presumably occupied. For the HZ mice (data not shown), the growth curve is in between that of the null and WT mice. These curves tends to plateau at concentrations of GM-CSF greater than 5 ng/mL, a dose that is known to result in occupancy of virtually all GM-CSF receptors (D.S.F., unpublished observations). In general, at concentrations of GM-CSF that occupy a small portion of the receptors, the ability of the three genotypes to be stratified by virtue of their proliferative response to GM-CSF is lost. As the dose of GM-CSF increases, normal tyrosine phosphorylation of STAT5A and STAT5B occurs, and proliferation reaches maximal levels in WT cells. Maximal differences are observed between cells of the null and WT mice during the logarithmic phase of the growth curve. Although it is known that STAT5 can bind to the chain of the GM-CSF/IL-3/IL-5 receptor family,32,33 the detailed mechanisms by which tyrosine phosphorylation of STAT5 and subsequent heterodimer formation occur are not known. It is conceivable that some cells may not respond to GM-CSF until certain levels of receptor occupancy occur, and this may be occurring at doses that result in occupancy of virtually all the receptors. Moreover, it has recently been shown that the direct interaction of STAT5 with the JH2 domain of Jaks may also be a mechanism for STAT binding and activation.34 Therefore, the degree of activation of a Jak and STAT5 at various concentrations of ligand may need to be re-explored. The availability of mice deficient in STAT5A and STAT5B will enable us to investigate more fully the precise mechanism and role of heterodimer formation in both gene expression and cell proliferation.
| |
FOOTNOTES |
Submitted April 17, 1997;
accepted June 16, 1997.
L.A.R. was supported by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and the Food and Drug Administration.
Address reprint requests to David S. Finbloom, MD, Division of Cytokine Biology, Center for Biologics Evaluation and Research, Food and Drug Administration, 29 Lincoln Dr MSC 4555, Bethesda, MD 20892-4555.
The publication costs of this article were defrayed in part by page
charge payment. This article must therefore be hearly marked
``advertisment'' in accordance with 18 U.S.C. section 1734 solely to
indicate this fact.
| |
ACKNOWLEDGMENT |
The authors acknowledge Lisa Garrett and Theresa Hernandez for their contributions in animal husbandry.
| |
REFERENCES |
1.
Finbloom DS,
Larner AC:
Induction of early response genes by interferons, interleukins, and growth factors by the tyrosine phosphorylation of latent transcription factors: Implications for inflammatory diseases.
Arthritis Rheum
38:877,
1995[Medline]
[Order article via Infotrieve]
2.
Darnell JE Jr,
Kerr IM,
Stark GR:
Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.
Science
264:1415,
1994[Abstract/Free Full Text]
3.
Larner AC,
Finbloom DS:
Protein tyrosine phosphorylation as a mechanism which regulates cytokine activation of early response genes.
Biochem Biophys Acta
1266:278,
1995[Medline]
[Order article via Infotrieve]
4.
Larner AC,
David M,
Feldman GM,
Igarashi K,
Hackett RH,
Webb DAS,
Sweitzer SM,
Petricoin EF III,
Finbloom DS:
Tyrosine phosphorylation of DNA binding proteins by multiple cytokines.
Science
261:1730,
1993[Abstract/Free Full Text]
5.
Wakao H,
Gouilleux F,
Groner B:
Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers prolactin response.
EMBO J
13:2182,
1994[Medline]
[Order article via Infotrieve]
6.
Gouilleux G,
Pallard C,
Dusanter-Fourt I,
Wakao H,
Haldosen L,
Norstedt G,
Levy D,
Groner B:
Prolactin, growth hormone, erythropoietin, and granulocyte-macrophage colony stimulating factor induce MGF-STAT5 DNA binding activity.
EMBO J
14:2005,
1995[Medline]
[Order article via Infotrieve]
7.
Pallard C,
Gouilleux F,
Benit L,
Coault L,
Souyri M,
Levy D,
Groner B,
Gisselbrecht S,
Dusanter-Fourt I:
Thrombopoietin activates a STAT5-like factor in hematopoietic cells.
EMBO J
14:2847,
1995[Medline]
[Order article via Infotrieve]
8.
Rosen RL,
Winestock KD,
Chen G,
Liu X,
Hennighausen L,
Finbloom DS:
Granulocyte-macrophage colony stimulating factor (GM-CSF) preferentially activates the 94-kD STAT5A and an 80-kD STAT5A isoform in human peripheral blood monocytes.
Blood
88:1206,
1996[Abstract/Free Full Text]
9.
Mui A,
Wakao H,
Kinoshita T,
Kitamura T,
Miyajima A:
Suppression of interleukin-3 induced gene expression by a C-terminal truncated STAT5: Role of STAT5 in proliferation.
EMBO J
15:2425,
1996[Medline]
[Order article via Infotrieve]
10.
Wang D,
Strabopodis D,
Teglund S,
Kitazawa J,
Ihle JN:
Naturally occurring dominant negative variants of STAT5.
Mol Cell Biol
16:6141,
1996[Abstract]
11.
Chretien S,
Varlet P,
Verdier F,
Govert S,
Cartron J,
Gisselbrecht S,
Mayeux P,
Lacombe C:
Erythropoietin-induced erythroid differentiation of the human erytroleukiemia cell line TF-1 correlates with impaired STAT5 activation.
EMBO J
15:4174,
1996[Medline]
[Order article via Infotrieve]
12.
Liu X,
Robinson GW,
Gouilleux F,
Groner B,
Hennighausen L:
Cloning and expression of STAT5 and an additional homologue (STAT5B) involved in prolactin signal transduction in mouse mammary tissue.
Proc Natl Acad Sci USA
92:8831,
1995[Abstract/Free Full Text]
13.
Azam M,
Erdjument-Bromage H,
Kreider BL,
Xia M,
Quelle F,
Basu R,
Saris C,
Tempst P,
Ihle JN,
Schindler C:
Interleukin-3 signals through multiple isoforms of STAT5.
EMBO J
14:1402,
1995[Medline]
[Order article via Infotrieve]
14.
Lin J,
Mietz J,
Modi WS,
John S,
Leonard WJ:
Cloning of human Stat5B. Reconstitution of interleukin-2 induced STAT5a and STAT5b DNA binding activity in COS-7 cells.
J Biol Chem
271:10738,
1996[Abstract/Free Full Text]
15.
Moriggl R,
Gouilleux-Gruart V,
Jahne R,
Berchtold S,
Gartmann C,
Liu X,
Hennighausen L,
Sotiropoulos A,
Groner B,
Gouilleux F:
Deletion of the carboxyl-terminal transactivation domain of MGF-STAT5 results in sustained DNA binding and a dominant negative effect.
Mol Cell Biol
16:5691,
1996[Abstract]
16.
Liu X,
Robinson GW,
Wagner K,
Garrett L,
Wynshaw-Boris A,
Hennighausen L:
Stat5a is mandatory for adult mammary gland development and lactogenesis.
Genes Dev
11:179,
1997[Abstract/Free Full Text]
17.
Meerpohl H,
Lohmann-Matthes M,
Fischer H:
Studies on the activation of mouse bone marrow-derived macrophages by the macrophage cytotoxicity factor (MCF).
Eur J Immunol
6:213,
1976[Medline]
[Order article via Infotrieve]
18.
Wilson KC,
Finbloom DS:
Interferon rapidly induces in human monocytes a DNA-binding factor that recognizes the response region within the promoter of the gene for the high-affinity Fc receptor.
Proc Natl Acad Sci USA
89:11964,
1992[Abstract/Free Full Text]
19.
Pearse RN,
Feinman R,
Ravetch JV:
Characterization of the promoter of the human gene encoding the high affinity IgG receptor: Transcriptional induction by -interferon is mediated through common DNA response elements.
Proc Natl Acad Sci USA
88:11305,
1991[Abstract/Free Full Text]
20.
Igarashi K,
Garotta G,
Ozmen L,
Ziemiecki A,
Wilks AF,
Harpur AG,
Larner AC,
Finbloom DS:
Interferon- induces tyrosine phosphorylation of interferon- receptor and regulated association of protein tyrosine kinases, Jak1 and Jak2, with its receptor.
J Biol Chem
269:14333,
1994[Abstract/Free Full Text]
21.
Yoshimura A,
Ohkubo T,
Kiguchi T,
Jenkins NA,
Gilbert DJ,
Copeland NG,
Hara T,
Miyajima A:
A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin-3 and erythropoietin receptors.
EMBO J
14:2816,
1995[Medline]
[Order article via Infotrieve]
22.
Lin EY,
Orlofsky A,
Wang H-W,
Reed JC,
Prystowsky MB:
A1, a Bc1-2 family member prolongs cell survival and permits myeloid differentiation.
Blood
87:983,
1996[Abstract/Free Full Text]
23.
Piechaczyk M,
Blanchard JM,
Marty L,
Dani C,
Panabieres F,
El Sabouty S,
Fort P,
Jeanteur P:
Post-transcriptional regulation of glyceraldehyde-3-phosphate-dehydrogenase gene expression in rat tissues.
Nucleic Acids Res
12:6951,
1984[Abstract/Free Full Text]
24.
Feinberg AP,
Vogelstein B:
A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity.
Anal Biochem
132:6,
1983[Medline]
[Order article via Infotrieve]
25.
Mosmann T:
Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays.
J Immunol Methods
65:55,
1983[Medline]
[Order article via Infotrieve]
26.
Liu X,
Robinson G,
Hennighausen L:
Activation of Stat5a and Stat5b by tyrosine phosphorylation is tightly linked to mammary gland differentiation.
Mol Endocrinol
10:1496,
1996[Abstract/Free Full Text]
27.
Mui AL,
Wakao H,
O'Farrell A-M,
Harada N,
Miyajima A:
Interleukin-3, granulocyte-macrophage colony stimulating factor and interleukin-5 transduce signals through two STAT5 homologs.
EMBO J
14:1166,
1995[Medline]
[Order article via Infotrieve]
28.
John S,
Robbins CM,
Leonard WJ:
An IL-2 response element in the human IL-2 receptor chain promoter is a composite element that binds STAT5, Elf-1, and HMG-I(Y) and a GATA family protein.
EMBO J
15:5627,
1996[Medline]
[Order article via Infotrieve]
29.
Xu X,
Sun YL,
Hoey T:
Cooperative DNA binding and sequence-selective recognition conferred by the STAT amino-terminal domain.
Science
273:794,
1996[Abstract]
30.
Vinkemeier U,
Cohen SL,
Moarefi I,
Chait BT,
Kuriyan J,
Darnell JE Jr:
DNA binding of in vitro activated Stat 1 alpha, Stat 1 beta and truncated Stat 1: interaction between NH2-terminal domains stabilizes binding of two dimers to tandem DNA sites.
EMBO J
15:5616,
1996[Medline]
[Order article via Infotrieve]
31.
Lin EY,
Orlofsky A,
Berger MS,
Prystowsky MB:
Characterization of A1, a novel hemopoietic-specific early-response gene with sequence similarity to bcl-2.
J Immunol
151:1979,
1993[Abstract]
32.
Woodcock JM,
Bagley CJ,
Zacharakis B,
Lopez AF:
A single tyrosine residue in the membrane proximal domain of the granulocyte-macrophage colony-stimulating factor, interleukin (IL)-3, and IL-5 receptor common -chain is necessary and sufficient for high affinity binding and signaling by all three ligands.
J Biol Chem
271:25999,
1996[Abstract/Free Full Text]
33.
Chin H,
Nakamura N,
Kamiyama R,
Miyasaka N,
Ihle JN,
Miura O:
Physical and functional interactions between STAT5 and the tyrosine phosphorylated receptors for erythropoietin and interleukin-3.
Blood
88:4415,
1996[Abstract/Free Full Text]
34.
Fujitani Y,
Hibi M,
Fukada T,
Takahashi-Tezuka M,
Yoshida H,
Yamaguchi T,
Sugiyama K,
Yamanaka Y,
Nakajima K,
Hirano T:
An alternative pathway for STAT activation that is mediated by the direct interaction between JAK and STAT.
Oncogene
14:751,
1997[Medline]
[Order article via Infotrieve]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Kimura, M. A. Rieger, J. M. Simone, W. Chen, M. C. Wickre, B.-M. Zhu, P. S. Hoppe, J. J. O'Shea, T. Schroeder, and L. Hennighausen
The transcription factors STAT5A/B regulate GM-CSF-mediated granulopoiesis
Blood,
November 19, 2009;
114(21):
4721 - 4728.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Sebastian, C. Herrero, M. Serra, J. Lloberas, M. A. Blasco, and A. Celada
Telomere Shortening and Oxidative Stress in Aged Macrophages Results in Impaired STAT5a Phosphorylation
J. Immunol.,
August 15, 2009;
183(4):
2356 - 2364.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Funakoshi-Tago, K. Tago, K. Sumi, M. Abe, E. Aizu-Yokota, T. Oshio, Y. Sonoda, and T. Kasahara
The Acute Lymphoblastic Leukemia-associated JAK2 L611S Mutant Induces Tumorigenesis in Nude Mice
J. Biol. Chem.,
May 8, 2009;
284(19):
12680 - 12690.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Skarica, T. Wang, E. McCadden, D. Kardian, P. A. Calabresi, D. Small, and K. A. Whartenby
Signal Transduction Inhibition of APCs Diminishes Th17 and Th1 Responses in Experimental Autoimmune Encephalomyelitis
J. Immunol.,
April 1, 2009;
182(7):
4192 - 4199.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tanimoto, Y. Murata, K.-Y. Wang, M. Tsutsui, K. Kohno, and Y. Sasaguri
Monocyte Chemoattractant Protein-1 Expression Is Enhanced by Granulocyte-Macrophage Colony-stimulating Factor via Jak2-Stat5 Signaling and Inhibited by Atorvastatin in Human Monocytic U937 Cells
J. Biol. Chem.,
February 22, 2008;
283(8):
4643 - 4651.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Carreras, S. Turner, V. Paharkova-Vatchkova, A. Mao, C. Dascher, and S. Kovats
Estradiol Acts Directly on Bone Marrow Myeloid Progenitors to Differentially Regulate GM-CSF or Flt3 Ligand-Mediated Dendritic Cell Differentiation
J. Immunol.,
January 15, 2008;
180(2):
727 - 738.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Schepers, D. van Gosliga, A. T. J. Wierenga, B. J. L. Eggen, J. J. Schuringa, and E. Vellenga
STAT5 is required for long-term maintenance of normal and leukemic human stem/progenitor cells
Blood,
October 15, 2007;
110(8):
2880 - 2888.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Yao, Y. Kanno, M. Kerenyi, G. Stephens, L. Durant, W. T. Watford, A. Laurence, G. W. Robinson, E. M. Shevach, R. Moriggl, et al.
Nonredundant roles for Stat5a/b in directly regulating Foxp3
Blood,
May 15, 2007;
109(10):
4368 - 4375.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Harir, C. Pecquet, M. Kerenyi, K. Sonneck, B. Kovacic, R. Nyga, M. Brevet, I. Dhennin, V. Gouilleux-Gruart, H. Beug, et al.
Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias
Blood,
February 15, 2007;
109(4):
1678 - 1686.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Schmerer, I. Torregroza, A. Pascal, M. Umbhauer, and T. Evans
STAT5 acts as a repressor to regulate early embryonic erythropoiesis
Blood,
November 1, 2006;
108(9):
2989 - 2997.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Nelson, S. R. Walker, W. Li, X. S. Liu, and D. A. Frank
Identification of Human STAT5-dependent Gene Regulatory Elements Based on Interspecies Homology
J. Biol. Chem.,
September 8, 2006;
281(36):
26216 - 26224.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Ye, N. Wolff, L. Li, S. Zhang, and R. L. Ilaria Jr
STAT5 signaling is required for the efficient induction and maintenance of CML in mice
Blood,
June 15, 2006;
107(12):
4917 - 4925.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Sekine, T. Yamamoto, T. Yumioka, K. Sugiyama, S. Tsuji, K. Oritani, K. Shimoda, M. Minoguchi, A. Yoshimura, and T. Matsuda
Physical and Functional Interactions between STAP-2/BKS and STAT5
J. Biol. Chem.,
March 4, 2005;
280(9):
8188 - 8196.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Nelson, S. R. Walker, J. V. Alvarez, and D. A. Frank
Isolation of Unique STAT5 Targets by Chromatin Immunoprecipitation-based Gene Identification
J. Biol. Chem.,
December 24, 2004;
279(52):
54724 - 54730.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Burke, A. Pridmore, N. Harraghy, A. Collick, J. Brown, and T. Mitchell
Transgenic Mice Showing Inflammation-Inducible Overexpression of Granulocyte Macrophage Colony-Stimulating Factor
Clin. Vaccine Immunol.,
May 1, 2004;
11(3):
588 - 598.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Magne, S. Caron, M. Charon, M.-C. Rouyez, and I. Dusanter-Fourt
STAT5 and Oct-1 Form a Stable Complex That Modulates Cyclin D1 Expression
Mol. Cell. Biol.,
December 15, 2003;
23(24):
8934 - 8945.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. J. Warby, S. M. Crowe, and A. Jaworowski
Human Immunodeficiency Virus Type 1 Infection Inhibits Granulocyte-Macrophage Colony-Stimulating Factor-Induced Activation of STAT5A in Human Monocyte-Derived Macrophages
J. Virol.,
December 1, 2003;
77(23):
12630 - 12638.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Snow, N. Abraham, M. C. Ma, B. G. Herndier, A. W. Pastuszak, and M. A. Goldsmith
Loss of Tolerance and Autoimmunity Affecting Multiple Organs in STAT5A/5B-Deficient Mice
J. Immunol.,
November 15, 2003;
171(10):
5042 - 5050.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. P. Shelburne, M. E. McCoy, R. Piekorz, V. Sexl, K.-H. Roh, S. M. Jacobs-Helber, S. R. Gillespie, D. P. Bailey, P. Mirmonsef, M. N. Mann, et al.
Stat5 expression is critical for mast cell development and survival
Blood,
August 15, 2003;
102(4):
1290 - 1297.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Benekli, M. R. Baer, H. Baumann, and M. Wetzler
Signal transducer and activator of transcription proteins in leukemias
Blood,
April 15, 2003;
101(8):
2940 - 2954.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Endo, A. Sasaki, M. Minoguchi, A. Joo, and A. Yoshimura
CIS1 Interacts with the Y532 of the Prolactin Receptor and Suppresses Prolactin-Dependent STAT5 Activation
J. Biochem.,
January 1, 2003;
133(1):
109 - 113.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Buitenhuis, B. Baltus, J.-W. J. Lammers, P. J. Coffer, and L. Koenderman
Signal transducer and activator of transcription 5a (STAT5a) is required for eosinophil differentiation of human cord blood-derived CD34+ cells
Blood,
January 1, 2003;
101(1):
134 - 142.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Shen and M. H. Kaplan
The Homeostasis But Not the Differentiation of T Cells Is Regulated by p27Kip1
J. Immunol.,
July 15, 2002;
169(2):
714 - 721.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Ghilardi, J. Li, J.-A. Hongo, S. Yi, A. Gurney, and F. J. de Sauvage
A Novel Type I Cytokine Receptor Is Expressed on Monocytes, Signals Proliferation, and Activates STAT-3 and STAT-5
J. Biol. Chem.,
May 3, 2002;
277(19):
16831 - 16836.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Zeng, Y. Aoki, M. Yoshida, K.-i. Arai, and S. Watanabe
Stat5B Shuttles Between Cytoplasm and Nucleus in a Cytokine-Dependent and -Independent Manner
J. Immunol.,
May 1, 2002;
168(9):
4567 - 4575.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Lehtonen, S. Matikainen, M. Miettinen, and I. Julkunen
Granulocyte-macrophage colony-stimulating factor (GM-CSF)-induced STAT5 activation and target-gene expression during human monocyte/macrophage differentiation
J. Leukoc. Biol.,
March 1, 2002;
71(3):
511 - 519.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. D. Bunting, H. L. Bradley, T. S. Hawley, R. Moriggl, B. P. Sorrentino, and J. N. Ihle
Reduced lymphomyeloid repopulating activity from adult bone marrow and fetal liver of mice lacking expression of STAT5
Blood,
January 15, 2002;
99(2):
479 - 487.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Snow, N. Abraham, M. C. Ma, N. W. Abbey, B. Herndier, and M. A. Goldsmith
STAT5 promotes multilineage hematolymphoid development in vivo through effects on early hematopoietic progenitor cells
Blood,
January 1, 2002;
99(1):
95 - 101.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Dif, E. Saunier, B. Demeneix, P. A. Kelly, and M. Edery
Cytokine-Inducible SH2-Containing Protein Suppresses PRL Signaling by Binding the PRL Receptor
Endocrinology,
December 1, 2001;
142(12):
5286 - 5293.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Socolovsky, H.-s. Nam, M. D. Fleming, V. H. Haase, C. Brugnara, and H. F. Lodish
Ineffective erythropoiesis in Stat5a-/-5b-/- mice due to decreased survival of early erythroblasts
Blood,
December 1, 2001;
98(12):
3261 - 3273.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Horikawa, H. Kaku, H. Nakajima, H. W. Davey, L. Henninghausen, I. Iwamoto, T. Yasue, A. Kariyone, and K. Takatsu
Essential Role of Stat5 for IL-5-Dependent IgH Switch Recombination in Mouse B Cells
J. Immunol.,
November 1, 2001;
167(9):
5018 - 5026.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bhattacharya, B. A. Stout, M. E. Bates, P. J. Bertics, and J. S. Malter
Granulocyte Macrophage Colony-Stimulating Factor and Interleukin-5 Activate STAT5 and Induce CIS1 mRNA in Human Peripheral Blood Eosinophils
Am. J. Respir. Cell Mol. Biol.,
March 1, 2001;
24(3):
312 - 316.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Watanabe, R. Zeng, Y. Aoki, T. Itoh, and K.-i. Arai
Initiation of polyoma virus origin-dependent DNA replication through STAT5 activation by human granulocyte-macrophage colony-stimulating factor
Blood,
March 1, 2001;
97(5):
1266 - 1273.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. F. Valledor, M. Comalada, J. Xaus, and A. Celada
The Differential Time-course of Extracellular-regulated Kinase Activity Correlates with the Macrophage Response toward Proliferation or Activation
J. Biol. Chem.,
March 15, 2000;
275(10):
7403 - 7409.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-i. Kagami, H. Nakajima, K. Kumano, K. Suzuki, A. Suto, K. Imada, H. W. Davey, Y. Saito, K. Takatsu, W. J. Leonard, et al.
Both Stat5a and Stat5b are required for antigen-induced eosinophil and T-cell recruitment into the tissue
Blood,
February 15, 2000;
95(4):
1370 - 1377.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kieslinger, I. Woldman, R. Moriggl, J. Hofmann, J.-C. Marine, J. N. Ihle, H. Beug, and T. Decker
Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation
Genes & Dev.,
January 15, 2000;
14(2):
232 - 244.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. C. Ward, I. Touw, and A. Yoshimura
The Jak-Stat pathway in normal and perturbed hematopoiesis
Blood,
January 1, 2000;
95(1):
19 - 29.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Matsumoto, Y. Seki, M. Kubo, S. Ohtsuka, A. Suzuki, I. Hayashi, K. Tsuji, T. Nakahata, M. Okabe, S. Yamada, et al.
Suppression of STAT5 Functions in Liver, Mammary Glands, and T Cells in Cytokine-Inducible SH2-Containing Protein 1 Transgenic Mice
Mol. Cell. Biol.,
September 1, 1999;
19(9):
6396 - 6407.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. P. de Groot, J. A.M. Raaijmakers, J.-W. J. Lammers, R. Jove, and L. Koenderman
STAT5 Activation by BCR-Abl Contributes to Transformation of K562 Leukemia Cells
Blood,
August 1, 1999;
94(3):
1108 - 1112.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Tanaka, K. Kaneko, H. Asao, H. Kasai, Y. Endo, T. Fujita, T. Takeshita, and K. Sugamura
Possible Involvement of a Novel STAM-associated Molecule "AMSH" in Intracellular Signal Transduction Mediated by Cytokines
J. Biol. Chem.,
July 2, 1999;
274(27):
19129 - 19135.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Ilaria Jr, R. G. Hawley, and R. A. Van Etten
Dominant Negative Mutants Implicate STAT5 in Myeloid Cell Proliferation and Neutrophil Differentiation
Blood,
June 15, 1999;
93(12):
4154 - 4166.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Ji, R. Guan, S. J. Frank, and J. L. Messina
Insulin Inhibits Growth Hormone Signaling via the Growth Hormone Receptor/JAK2/STAT5B Pathway
J. Biol. Chem.,
May 7, 1999;
274(19):
13434 - 13442.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Nieborowska-Skorska, M. A. Wasik, A. Slupianek, P. Salomoni, T. Kitamura, B. Calabretta, and T. Skorski
Signal Transducer and Activator of Transcription (STAT)5 Activation by BCR/ABL Is Dependent on Intact Src Homology (SH)3 and SH2 Domains of BCR/ABL and Is Required for Leukemogenesis
J. Exp. Med.,
April 19, 1999;
189(8):
1229 - 1242.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Reed, M. Ikegami, E. R. Cianciolo, W. Lu, P. S. Cho, W. Hull, A. H. Jobe, and J. A. Whitsett
Aerosolized GM-CSF ameliorates pulmonary alveolar proteinosis in GM-CSF-deficient mice
Am J Physiol Lung Cell Mol Physiol,
April 1, 1999;
276(4):
L556 - L563.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N.A. NICOLA, S.E. NICHOLSON, D. METCALF, J.-G. ZHANG, M. BACA, A. FARLEY, T.A. WILLSON, R. STARR, W. ALEXANDER, and D.J. HILTON
Negative Regulation of Cytokine Signaling by the SOCS Proteins
Cold Spring Harb Symp Quant Biol,
January 1, 1999;
64(0):
397 - 404.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. Boucheron, S. Dumon, S. C. R. Santos, R. Moriggl, L. Hennighausen, S. Gisselbrecht, and F. Gouilleux
A Single Amino Acid in the DNA Binding Regions of STAT5A and STAT5B Confers Distinct DNA Binding Specificities
J. Biol. Chem.,
December 18, 1998;
273(51):
33936 - 33941.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Dong, X. Liu, J. P. de Koning, I. P. Touw, L. Henninghausen, A. Larner, and P. M. Grimley
Stimulation of Stat5 by Granulocyte Colony-Stimulating Factor (G-CSF) Is Modulated by Two Distinct Cytoplasmic Regions of the G-CSF Receptor
J. Immunol.,
December 15, 1998;
161(12):
6503 - 6509.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Imada, E. T. Bloom, H. Nakajima, J. A. Horvath-Arcidiacono, G. B. Udy, H. W. Davey, and W. J. Leonard
Stat5b Is Essential for Natural Killer Cell-mediated Proliferation and Cytolytic Activity
J. Exp. Med.,
December 7, 1998;
188(11):
2067 - 2074.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. F. Seymour, C. G. Begley, U. Dirksen, J. J. Presneill, N. A. Nicola, P. E. Moore, O. D. Schoch, P. vanAsperen, B. Roth, S. Burdach, et al.
Attenuated Hematopoietic Response to Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Acquired Pulmonary Alveolar Proteinosis
Blood,
October 15, 1998;
92(8):
2657 - 2667.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Verdier, R. Rabionet, F. Gouilleux, C. Beisenherz-Huss, P. Varlet, O. Muller, P. Mayeux, C. Lacombe, S. Gisselbrecht, and S. Chretien
A Sequence of the CIS Gene Promoter Interacts Preferentially with Two Associated STAT5A Dimers: a Distinct Biochemical Difference between STAT5A and STAT5B
Mol. Cell. Biol.,
October 1, 1998;
18(10):
5852 - 5860.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
Y. Okajima, I. Matsumura, T. Nishiura, K. Hashimoto, H. Yoshida, J. Ishikawa, H. Wakao, A. Yoshimura, Y. Kanakura, Y. Tomiyama, et al.
Insulin-like Growth Factor-I Augments Erythropoietin-induced Proliferation through Enhanced Tyrosine Phosphorylation of STAT5
J. Biol. Chem.,
September 4, 1998;
273(36):
22877 - 22883.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Adachi and R. Alam
The mechanism of IL-5 signal transduction
Am J Physiol Cell Physiol,
September 1, 1998;
275(3):
C623 - C633.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. C. Gregory, N. Jiang, K. Todokoro, J. Crouse, R. E. Pacifici, and D. M. Wojchowski
Erythropoietin Receptor and STAT5-Specific Pathways Promote SKT6 Cell Hemoglobinization
Blood,
August 15, 1998;
92(4):
1104 - 1118.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Matsumura, K. Nakajima, H. Wakao, S. Hattori, K. Hashimoto, H. Sugahara, T. Kato, H. Miyazaki, T. Hirano, and Y. Kanakura
Involvement of Prolonged Ras Activation in Thrombopoietin-Induced Megakaryocytic Differentiation of a Human Factor-Dependent Hematopoietic Cell Line
Mol. Cell. Biol.,
July 1, 1998;
18(7):
4282 - 4290.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. C. Mulloy, T.-S. Migone, T. M. Ross, N. Ton, P. L. Green, W. J. Leonard, and G. Franchini
Human and Simian T-Cell Leukemia Viruses Type 2 (HTLV-2 and STLV-2pan-p) Transform T Cells Independently of Jak/STAT Activation
J. Virol.,
May 1, 1998;
72(5):
4408 - 4412.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. B. Ehret, P. Reichenbach, U. Schindler, C. M. Horvath, S. Fritz, M. Nabholz, and P. Bucher
DNA Binding Specificity of Different STAT Proteins. COMPARISON OF IN VITRO SPECIFICITY WITH NATURAL TARGET SITES
J. Biol. Chem.,
February 23, 2001;
276(9):
6675 - 6688.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
Abstract
Introduction
Abstract